National Marrow Donor Program, Magenta in cell therapy platform and service access deal

The Be The Match BioTherapies subsidiary of the National Marrow Donor Program (Minneapolis, Minn.) granted Magenta Therapeutics Inc. (Cambridge, Mass.) non-exclusive access to its cell therapy delivery platform, industry relationships and clinical trial design and management expertise, as well as patient outcomes data from the National Marrow Donor Program’s marrow registry.

Be The Match provides cell sourcing for clinical development of allogeneic therapies, and manages a clinical outcomes database for autologous and allogeneic hematopoietic cell transplants...